Rani Therapeutics Holdings, Inc.
RANI evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Market Cap:
- $118.4M
- Lead Asset:
- rt-102 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for RANI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RANI
Rani Therapeutics Holdings, Inc. (RANI) is a clinical-stage biotherapeutics company developing an oral delivery platform (RaniPill) to replace injections for biologics and drugs, with no approved products and limited revenue.
Key risk: Cash runway risk
BioSniper Score
Based on 4 of 6 signals
Market Cap
$118.4M
Cash Runway
—
Lead Asset
rt-102 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 4 clinical trials for Rani Therapeutics Holdings, Inc..
Similar companies
Rani Therapeutics Holdings, Inc. (RANI) is a clinical-stage biotherapeutics company developing an oral delivery platform (RaniPill) to replace injections for biologics and drugs, with no approved products and limited revenue.
- Cash & equivalents of $4.9M as of 2026-06-30 [sec]
- Total revenue of $1.7M and net loss of $7.4M for the six months ended June 30, 2026 [sec]
- Shareholders' equity of $39.2M as of 2026-06-30 [sec]
- Phase 1 trial initiated for RT-114 (oral GLP-1/GLP-2 agonist) in December 2025; initial data showed >150% oral bioavailability vs. subcutaneous dosing [news · 2026-08-13]
- Completed a $20M registered direct offering in May 2026 [news · 2026-08-13]
What works
- RaniPill platform is drug-agnostic and designed to deliver antibodies, proteins, peptides, and oligonucleotides orally, potentially replacing injections [sec_mda · as of 2026-08-13]
- Positive initial Phase 1a data for RT-114 showed oral bioavailability exceeding 150% relative to matched subcutaneous dosing [news · 2026-08-13]
- Strategic collaborations with Chugai, ProGen, and PegBio provide non-dilutive funding and pipeline expansion [sec_mda · as of 2026-08-13]
- Completed a $20M registered direct offering in May 2026, providing near-term capital [news · 2026-08-13]
What to weigh
- No products approved for sale and no revenue from product sales; profitability depends on successful development years away [sec_mda · as of 2026-08-13]
- Cash position of $4.9M as of 2026-06-30 is low relative to net losses; company anticipates needing substantial additional capital [sec_mda · as of 2026-08-13]
- Net loss of $7.4M for the six months ended June 30, 2026, with limited revenue of $1.7M [sec]
- No commercial organization or distribution capabilities established; no experience marketing a product [sec_mda · as of 2026-05-15]
From the filings
Quoted directly from source documents.
RaniPill platform is drug-agnostic and designed for oral delivery of biologics
“Our technology comprises a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides.”
SEC MD&A · August 13, 2026
RT-114 Phase 1a showed >150% oral bioavailability vs. subcutaneous
“Announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing”
News · August 13, 2026
Company has no approved products and no product revenue
“We do not have any products approved for sale, and we have not yet generated any revenue from sales of a commercial product.”
SEC MD&A · August 13, 2026
Company completed a $20M registered direct offering in May 2026
“Completed a $20 million registered direct offering”
News · August 13, 2026
Catalyst timeline
- 2025-12-30 · Phase 1 start for RT-114 — Phase 1 study initiated to evaluate safety, tolerability, PK/PD of RT-114 in healthy subjects.
Risks & what to watch (3)›
Key risks
- Cash runway risk — Cash of $4.9M as of 2026-06-30 may be insufficient given net loss of $7.4M in six months; substantial additional capital needed [sec_mda · as of 2026-08-13]
- No approved products — No products approved for sale; no revenue from product sales; profitability depends on successful development years away [sec_mda · as of 2026-08-13]
- Dependence on partnerships — Success depends on collaborations with Chugai, ProGen, PegBio; failure to receive milestones could impact funding [sec_mda · as of 2026-08-13]
What to watch
- Additional Phase 1a data for RT-114 expected by end of 2026 [news · 2026-08-13]
- Progress of RaniPill HC development and ability to scale manufacturing [sec_mda · as of 2026-08-13]
- Ability to secure additional financing given cash burn rate [sec_mda · as of 2026-08-13]
- Milestone payments from Chugai, ProGen, and PegBio collaborations [sec_mda · as of 2026-08-13]
Sources: Catalysts · News · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Rani Therapeutics Holdings, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Rani Therapeutics Holdings, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.33 · 0% dilution
Lead: Phase 1
4 candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 10.4%
- Days to cover
- 7.4
- Shares short
- 10,113,183
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RANI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Rani Therapeutics Holdings, Inc.?
Rani Therapeutics Holdings, Inc. (RANI) is a clinical-stage biotherapeutics company developing an oral delivery platform (RaniPill) to replace injections for biologics and drugs, with no approved products and limited revenue.
What is Rani Therapeutics Holdings, Inc.'s lead drug candidate?
Rani Therapeutics Holdings, Inc.'s most advanced tracked candidate is rt-102 (Phase 1) for Osteoporosis.
Who is the CEO of Rani Therapeutics Holdings, Inc.?
Mr. Talat Imran is the chief executive officer of Rani Therapeutics Holdings, Inc. (RANI).
Where is Rani Therapeutics Holdings, Inc. headquartered?
Rani Therapeutics Holdings, Inc. (RANI) is headquartered in San Jose, CA, United States.
What therapeutic areas does Rani Therapeutics Holdings, Inc. focus on?
Rani Therapeutics Holdings, Inc. develops therapies across Oncology, Immunology, Metabolic, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.